What KOFA does

KOFA (广州科方生物技术股份有限公司 / Guangzhou Kofa Biotechnology Co., Ltd.) is a privately-held Chinese in vitro diagnostics (IVD) manufacturer founded in 2004 and headquartered in Guangzhou Zhongxin Knowledge City. The company develops, manufactures, and sells diagnostic reagents and instruments across four technology platforms: chemiluminescence immunoassay, biochemistry, fluorescence immunochromatography, and integrated biochemical-immune assembly lines. Its portfolio spans the V919 ultra-high-speed chemiluminescence analyzer (China's first 800T/H unit, scalable to 3200T/H in 4-unit cascade), the KF3200 / ELF / BRS-9000 assembly line series, AI-120 / AI-180 chemiluminescence analyzers, the 微测 II/III/V fluorescence series, and the AM-200 to AM-800 biochemistry series, supported by over 200 NMPA-registered reagents covering liver/kidney function, cardiovascular, lipids, diabetes, genetic diseases, tumor markers, thyroid, infection, and inflammation panels.

The company operates a sales-led go-to-market model with direct sales to hospital clinical laboratories and third-party testing centers, supplemented by a regional distributor network across China. It is a National High-tech Enterprise with 60+ valid patents and an approved post-doctoral research station (2024), and participates in flagship industry events including CACLP, NCLM, and academic conferences. Quality validation is anchored in domestic NIFDC proficiency testing (17 biochemical indicators passed at full marks in 2024 and 2025) and 102 items in 2021 provincial EQA at 100% compliance, including international IFCC-RELA comparisons.

KOFA's end customers are Chinese healthcare providers — primarily hospital clinical laboratories and third-party independent testing centers — purchasing both capital instruments (analyzers, assembly lines) and recurring reagent consumables. No revenue, headcount, or funding data is publicly disclosed. The most recent strategic move is international market entry via WHX Labs Dubai 2026, while the core revenue base remains the domestic Chinese IVD market.

Name

KOFA

Legal name

广州科方生物技术股份有限公司

Website

https://gzkofa.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

101–250 employees

Short description

KOFA is a privately-held Chinese IVD manufacturer (founded 2004, Guangzhou) developing chemiluminescence, biochemistry, fluorescence, and assembly-line diagnostic platforms with 200+ registered reagents, serving hospital clinical laboratories and third-party testing centers across China.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD) Reagents and Instruments

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)

Keywords

• In vitro diagnostics
• Chemiluminescence immunoassay
• Clinical chemistry reagents
• Automated immunoassay analyzers
• Diagnostic testing platforms

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IVD Reagent Sales: Sale of in vitro diagnostic reagents covering liver/kidney function, cardiovascular disease, lipids, diabetes, genetic diseases, tumor markers, thyroid function and other detection areas. The company holds 200+ registration certificates providing a broad product portfolio.
2. IVD Instrument Sales: Sale and distribution of diagnostic instruments including chemiluminescence analyzers (V919, AI-180, AI-120S, AI-120), biochemical analyzers (AM series), fluorescence immunoassay analyzers (微测III, 微测V, 微测II), and automated assembly lines

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

KOFA (Guangzhou Kofa Biotechnology Co., Ltd.) develops, manufactures, and sells in vitro diagnostic (IVD) reagents and instruments through four technology platforms: chemiluminescence immunoassay, biochemical-immune assembly line, fluorescence immunochromatography, and biochemical analysis. The company sells diagnostic analyzers (e.g., V919 ultra-high-speed chemiluminescence analyzer at 800T/H, KF3200 assembly line, AI-120S/AI-180/AI-120, micro-test series, AM series) along with more than 200 registered diagnostic reagent kits covering liver/kidney function, cardiovascular disease, tumor markers, thyroid function, diabetes, inflammation, and infectious disease testing, primarily to hospitals, clinical laboratories, and third-party testing centers across China.

Product overview

广州科方生物技术股份有限公司（KOFA）是一家专注于体外诊断试剂及仪器（IVD）研发、制造、销售和服务的高新技术企业，成立于2004年，总部位于广州中新知识城。公司建立了四大核心技术平台：生化免疫流水线平台、化学发光检测平台、荧光免疫层析平台、生化诊断技术平台。核心产品包括V919超高速全自动化学发光免疫分析仪（国内首家800速，800T/H）、KF3200/ELF系列生化免疫流水线（占地仅3.86m²，发光800测速+生化2400测速）、AI系列化学发光分析仪（AI-120S/AI-180/AI-120）、微测系列荧光免疫分析仪（微测II/III/V，覆盖300T/H高速检测）、AM系列全自动生化分析仪（200-800T/H全系列覆盖）。公司拥有超过200项注册产品，检测系列涵盖肝肾功能、心血管疾病、血脂、糖尿病、遗传病、肿瘤、甲功、感染、炎症、血栓等多个领域，广泛应用于全国各级医疗机构。

Differentiator

Problem solved

Functional benefit

Products and services

• V919 Ultra-High-Speed Fully Automated Chemiluminescence Immunoassay Analyzer Ultra-high-speed fully automated chemiluminescence immunoassay analyzer with single-module throughput of 800T/H and 4-unit cascade up to 3200T/H, based on acridinium ester direct chemiluminescence. First results in 9 minutes. Covers tumor markers, thyroid function, sex hormones, cardiovascular, inflammation, liver fibrosis, thrombosis, cytokines, and growth metabolism detection series. Supports whole-blood direct testing for clinical laboratories and third-party testing centers.
• KF3200 Ultra-High-Speed Biochemical-Immune Assembly Line Ultra-high-speed biochemical-immune assembly line combining the V919 immunoassay module and AS-2450 biochemical module, occupying only 3.86m² while achieving 800 chemiluminescence + 2400 biochemical tests/hour throughput. Supports flexible cascading of 2 to 4 biochemical or immunoassay modules for clinical laboratories and high-volume testing centers.
• ELF Series Biochemical-Immune Assembly Line (ELF 3200/3800/6000/6200/6800)

Quantifiable outcome

• V919 achieves 800 tests/hour single module speed, 3200 tests/hour with 4-unit cascade, with first result in 9 minutes and precision CV ≤2%
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability4 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• China Medical Inspection Association (中华医学会)coreGTM or Marketing Partner · 22 August 2024KOFA exhibited at NCLM 2024 (18th National Clinical Laboratory Academic Conference) showcasing the KF3200 ultra-high-speed biochemical-immune assembly line to laboratory directors and medical professionals nationwide.
• Chinese Society of Laboratory Medicine (中华医学会检验医学分会)coreGTM or Marketing Partner · 29 June 2024KOFA participated in the Guangdong Immunology Academic Conference where product and market director Li Jiahui presented on 'Sepsis Detection Frontiers: Application of High-Speed Chemiluminescence in Multi-marker Combined Detection', showcasing products to laboratory professionals.
• Huizhou Health Vocational and Technical College (惠州卫生职业技术学院)minorStrategic or Co-development Partner · 30 December 2019KOFA established the 'Kofa Scholarship' at the college starting from 2014, awarding outstanding students. The scholarship has been successfully held for six sessions by 2019, supporting students in medical laboratory studies.
• Guangdong Medical University (广东医科大学)coreStrategic or Co-development Partner · 16 July 2018KOFA and Guangdong Medical University established a practical teaching base partnership in 2018. The university-enterprise collaboration began in 2012 with KOFA setting up dedicated scholarships and providing research funding. The partnership provides students with hands-on practical training opportunities in IVD manufacturing and testing.
• Guangdong Education Foundation (广东省教育基金会)minorStrategic or Co-development PartnerKOFA partners with Guangdong Education Foundation for scholarship programs at Guangdong Medical University and Huizhou Health Vocational and Technical College, demonstrating corporate social responsibility.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• YHLO Biotech: Shenzhen YHLO Biotech is a Chinese IVD specialist focused on chemiluminescence immunoassay instruments and reagent panels (autoimmune, infectious disease, fertility). YHLO's product mix and target customers overlap closely with KOFA's chemiluminescence and fluorescence immunochromatography lines.
• Maccura Biotechnology: Maccura is a Chinese IVD manufacturer providing clinical chemistry, immunoassay, hematology, and coagulation platforms. Maccura's biochemical and chemiluminescence portfolios serve the same hospital and third-party laboratory customers as KOFA, making it a comparable full-menu domestic IVD peer.
• Autobio Diagnostics: Autobio is a major Chinese IVD player offering chemiluminescence immunoassay, microbiology, and clinical chemistry systems with a similar hospital-laboratory customer base. Like KOFA, Autobio competes on automated immunoassay throughput and broad reagent menus, and is a direct domestic rival in mid- and high-tier hospital bids.
• Wantai Biological Pharmacy: Wantai Biological Pharmacy is a Chinese IVD company with diagnostic reagent products in infectious disease, immunology, and clinical chemistry categories. Wantai competes with KOFA in Chinese hospital and clinical laboratory reagent markets, particularly in immunoassay and infectious disease testing.
• Snibe (Shenzhen New Industries Biomedical Engineering): Shenzhen New Industries Biomedical Engineering (Snibe) is a leading Chinese chemiluminescence IVD company directly competing with KOFA in immunoassay analyzers and reagents across tumor markers, thyroid, hormones, and infectious disease. Both firms serve Chinese hospitals and third-party labs with comparable throughput platforms, making Snibe the closest product-line competitor.

Broad incumbents

• Mindray: Mindray is China's largest medical device and IVD company, offering chemiluminescence, biochemistry, hematology, and integrated lab automation to hospitals globally. Its IVD division directly competes with KOFA in domestic hospital bids, but Mindray operates at substantially larger scale and across multiple device categories.
• Siemens Healthineers: Siemens Healthineers operates the Atellica, ADVIA Centaur, and Dimension immunoassay/chemistry platforms globally and in Chinese hospitals. Its broad lab diagnostics portfolio overlaps with KOFA's chemiluminescence and biochemistry systems, but Siemens brings substantially larger scale and integration.
• Roche Diagnostics: Roche Diagnostics is the global IVD leader with cobas immunoassay and clinical chemistry platforms that anchor many Chinese tertiary hospitals. KOFA's V919 and KF3200 compete in the same high-throughput hospital segment but against Roche's far larger installed base and brand equity.
• Beckman Coulter Diagnostics: Beckman Coulter (a Danaher company) supplies the DxI, Access, and AU immunoassay and clinical chemistry platforms to Chinese hospitals and reference labs. Its broad IVD menu and automation capabilities compete directly with KOFA's chemiluminescence and biochemistry systems.
• Abbott Diagnostics: Abbott Diagnostics provides the Architect, Alinity, and i-STAT immunoassay and clinical chemistry platforms used in Chinese hospital and reference labs. Abbott represents a multinational incumbent competing for the same high-throughput lab automation contracts as KOFA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/KOFABiotech

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KOFA